U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C5H7O3.Ca.2H2O
Molecular Weight 306.323
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CALCIUM LEVULINATE

SMILES

O.O.[Ca++].CC(=O)CCC([O-])=O.CC(=O)CCC([O-])=O

InChI

InChIKey=WQFDRFDIWAMOPA-UHFFFAOYSA-L
InChI=1S/2C5H8O3.Ca.2H2O/c2*1-4(6)2-3-5(7)8;;;/h2*2-3H2,1H3,(H,7,8);;2*1H2/q;;+2;;/p-2

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details

Anhydrous dibasic calcium phosphate is a calcium salt of phosphoric acid. It is used as a diluent in pharmaceutical industry, in some toothpastes as a polishing agent. Calcium phosphate is generally recognized as safe by FDA. Dibasic calcium phosphate is ised as a supplement to treat conditions associated with calcium deficit, such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany)

Originator

Approval Year

1921
1467
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Not Provided
504
Unknown

Approved Use

Unknown
Palliative
Phase I
428
Unknown

Approved Use

Unknown
Palliative
Phase I
428
Unknown

Approved Use

Unknown
Primary
Approved
8429
Unknown

Approved Use

Hypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred
PubMed

PubMed

TitleDatePubMed
1,25 dihydroxyvitamin D3 enhances the calcium response of keratinocytes.
1999 Feb
Characterization of the human cysteinyl leukotriene CysLT1 receptor.
1999 Jun 24
Oim mice exhibit altered femur and incisor mineral composition and decreased bone mineral density.
2000 Aug
Regulation of Na/K-ATPase beta1-subunit gene expression by ouabain and other hypertrophic stimuli in neonatal rat cardiac myocytes.
2000 Dec
Inactivation properties of human recombinant class E calcium channels.
2000 Feb
Regulation of LPA-promoted myofibroblast contraction: role of Rho, myosin light chain kinase, and myosin light chain phosphatase.
2000 Feb 1
alpha(1E) subunits form the pore of three cerebellar R-type calcium channels with different pharmacological and permeation properties.
2000 Jan 1
Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells.
2000 Jan 7
NAIP interacts with hippocalcin and protects neurons against calcium-induced cell death through caspase-3-dependent and -independent pathways.
2000 Jul 17
Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin.
2000 Nov
Pharmacological blockade of ERG K(+) channels and Ca(2+) influx through store-operated channels exerts opposite effects on intracellular Ca(2+) oscillations in pituitary GH(3) cells.
2000 Nov
Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats.
2000 Nov 10
Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement.
2000 Oct 15
Pilocarpine-induced status epilepticus causes N-methyl-D-aspartate receptor-dependent inhibition of microsomal Mg(2+)/Ca(2+) ATPase-mediated Ca(2+) uptake.
2000 Sep
Ca2+-induced contraction of cat esophageal circular smooth muscle cells.
2001 Apr
Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity.
2001 Apr 27
Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations.
2001 Apr 7
Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells.
2001 Aug
Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow.
2001 Feb 9
Functional expression and characterization of a voltage-gated CaV1.3 (alpha1D) calcium channel subunit from an insulin-secreting cell line.
2001 Jul
Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine.
2001 Jul
Analysis of the native quaternary structure of vanilloid receptor 1.
2001 Jul 27
Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components.
2001 Jun
[Acute renal failure caused by hypercalcemia].
2001 Jun 10
Long-term alteration of calcium homeostatic mechanisms in the pilocarpine model of temporal lobe epilepsy.
2001 Jun 8
Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors.
2001 Mar 15
Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes.
2001 Mar 2
RGS4 inhibits platelet-activating factor receptor phosphorylation and cellular responses.
2001 Mar 27
Activating mutations of the calcium-sensing receptor: management of hypocalcemia.
2001 Nov
Regression of ventral striatum hypometabolism after calcium/calcitriol therapy in paroxysmal kinesigenic choreoathetosis due to idiopathic primary hypoparathyroidism.
2001 Nov
Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors.
2001 Nov 1
Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis.
2001 Nov 30
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.
2001 Oct
Familial intrahepatic cholestasis 1: studies of localization and function.
2001 Oct
Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism.
2001 Sep
CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells.
2002 Feb
Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene.
2002 Feb
Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.
2002 Jul
Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent.
2002 Jul 5
Human kidney diamine oxidase: heterologous expression, purification, and characterization.
2002 Jun
Expression of functional CCR and CXCR chemokine receptors in podocytes.
2002 Jun 15
Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart.
2002 Mar
Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products.
2002 May 15
Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons.
2002 Nov 4
Henri Moissan: winner of the Nobel Prize for Chemistry 1906.
2006 Oct 20
Patents

Patents

03966773
137
03974176
93
03981818
91
04008309
69
04028407
67
04041173
67
04042702
91
04058507
67
04063023
67
06485737
67
06497902
67
08637538
67
20090030026
67
20130174651
67
JP2017071731
67
US2143359
67

Sample Use Guides

In Vivo Use Guide
oral: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid). inhalation: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (calcium lactate inhalation powder (CLIP) formulation) (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.
Route of Administration: Other
In Vitro Use Guide
Unknown
Name Type Language
CALCIUM LEVULINATE
USP   EP  
Official Name English
CALCIUM LEVULINATE DIHYDRATE [EP MONOGRAPH]
Common Name English
CALCIUM LEVULINATE [VANDF]
Common Name English
PENTANOIC ACID, 4-OXO-, CALCIUM SALT (2:1), DIHYDRATE
Common Name English
CALCIUM LEVULINATE [USP MONOGRAPH]
Common Name English
CALCIUM LEVULINATE DIHYDRATE
EP  
Systematic Name English
CALCIUM LEVULINATE [MART.]
Common Name English
Calcium levulinate dihydrate [WHO-DD]
Common Name English
Calcium levulinate (1:2) dihydrate
Common Name English
CALCIUM LEVULINATE DIHYDRATE [EP IMPURITY]
Common Name English
CALCIUM LEVULINATE [USP-RS]
Common Name English
Code System Code Type Description
PUBCHEM
68651
Created by admin on Fri Dec 15 15:08:24 GMT 2023 , Edited by admin on Fri Dec 15 15:08:24 GMT 2023
PRIMARY
EVMPD
SUB11776MIG
Created by admin on Fri Dec 15 15:08:24 GMT 2023 , Edited by admin on Fri Dec 15 15:08:24 GMT 2023
PRIMARY
ChEMBL
CHEMBL1235931
Created by admin on Fri Dec 15 15:08:24 GMT 2023 , Edited by admin on Fri Dec 15 15:08:24 GMT 2023
PRIMARY
MESH
C032246
Created by admin on Fri Dec 15 15:08:24 GMT 2023 , Edited by admin on Fri Dec 15 15:08:24 GMT 2023
PRIMARY
FDA UNII
T6133SO781
Created by admin on Fri Dec 15 15:08:24 GMT 2023 , Edited by admin on Fri Dec 15 15:08:24 GMT 2023
PRIMARY
DRUG CENTRAL
4844
Created by admin on Fri Dec 15 15:08:24 GMT 2023 , Edited by admin on Fri Dec 15 15:08:24 GMT 2023
PRIMARY
RS_ITEM_NUM
1086935
Created by admin on Fri Dec 15 15:08:24 GMT 2023 , Edited by admin on Fri Dec 15 15:08:24 GMT 2023
PRIMARY
NCI_THESAURUS
C76833
Created by admin on Fri Dec 15 15:08:24 GMT 2023 , Edited by admin on Fri Dec 15 15:08:24 GMT 2023
PRIMARY
DRUG BANK
DB13800
Created by admin on Fri Dec 15 15:08:24 GMT 2023 , Edited by admin on Fri Dec 15 15:08:24 GMT 2023
PRIMARY
EPA CompTox
DTXSID8046539
Created by admin on Fri Dec 15 15:08:24 GMT 2023 , Edited by admin on Fri Dec 15 15:08:24 GMT 2023
PRIMARY
RXCUI
47624
Created by admin on Fri Dec 15 15:08:24 GMT 2023 , Edited by admin on Fri Dec 15 15:08:24 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C1505
Created by admin on Fri Dec 15 15:08:24 GMT 2023 , Edited by admin on Fri Dec 15 15:08:24 GMT 2023
CONCEPT Dietary Supplement
CAS
5743-49-7
Created by admin on Fri Dec 15 15:08:24 GMT 2023 , Edited by admin on Fri Dec 15 15:08:24 GMT 2023
PRIMARY
EVMPD
SUB13187MIG
Created by admin on Fri Dec 15 15:08:24 GMT 2023 , Edited by admin on Fri Dec 15 15:08:24 GMT 2023
PRIMARY
SMS_ID
100000076387
Created by admin on Fri Dec 15 15:08:24 GMT 2023 , Edited by admin on Fri Dec 15 15:08:24 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of CALCIUM CATION
PARENT (SALT/SOLVATE)
Structure of LEVULINIC ACID
SUBSTANCE RECORD
Structure of CALCIUM LEVULINATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966